FDA extends review of multiple sclerosis drug ofatumumab | CredoWeb

Articol

FDA extends review of multiple sclerosis drug ofatumumab

FDA extends review of multiple sclerosis drug ofatumumab

Farmacie Neurologie Oncologie

multiple sclerosis Novartis MS Ofatumumab Arzerra leukemia

Partajați:

Comentarii